Recent briefings through mid-June 2026 did not identify discrete Pfizer-specific corporate news events in the 30 days preceding this report's generation date. Broader market context included heightened geopolitical uncertainty following reported US-Iran tensions and intercepted missiles aimed at American forces in Kuwait [Brief - 2026-06-01]. A separate development noted GSK's Bexsero vaccine selected for a UK meningitis B programme targeting approximately one million students, a programme with no direct Pfizer involvement [Brief - 2026-06-14].
Pfizer's trailing twelve-month revenue stood at $63.32 billion as of the most recent filing, reflecting year-over-year growth of 5.37%. Net income for the same period was $7.49 billion, producing a net margin of 11.83% and an operating margin of 35.40%. EPS declined 9.62% year-over-year. The company held $1.70 billion in cash against total debt of $64.46 billion. The price-to-earnings ratio was recorded at 19.88 [SEC 10-Q - PFE - 2026-03-29].
Insider activity in June 2026 comprised a single transaction, directionally a sale, with a net value of approximately -$51,400 [SEC Form 4 - PFE - 2026-06]. Institutional ownership showed divergent moves in the most recent 13F cycle. Citadel reduced its PFE position by 17%, while AQR Capital added 21% to its position and Millennium added 9.9% [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Millennium - Q1 2026]. These material position changes in aggregate triggered the generation of this report.
The US 10-year Treasury yield stood at 4.47% and the 2-year yield at 4.07%, producing a normal yield curve spread of approximately 40 basis points [FRED DGS10] [FRED DGS2]. This rate environment is relevant context for pharmaceutical issuers carrying significant debt loads, given Pfizer's total debt of $64.46 billion relative to its cash position of $1.70 billion as reported in the most recent quarterly filing [SEC 10-Q - PFE - 2026-03-29].